Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences Inc (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company pioneering therapies targeting lipid-signaling pathways, including innovative approaches to cancer support care and neuropathic pain management. This page provides investors and researchers with verified updates on the company’s progress in developing novel treatments for conditions with high unmet medical needs.
Access comprehensive coverage of clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection includes press releases about Artelo’s proprietary cocrystal technology, FABP5 inhibitor program, and advancements in cannabinoid-based therapeutics – all essential for tracking the company’s pipeline evolution.
Stay informed about critical updates including Phase trial results, intellectual property filings, and collaborations with global research institutions. Bookmark this page for real-time insights into how Artelo Biosciences is advancing treatments for chemotherapy-induced neuropathy, cancer-related anorexia, and inflammatory conditions through cutting-edge science.
Artelo Biosciences (Nasdaq: ARTL) has published significant preclinical data for ART12.11, their proprietary CBD:TMP cocrystal, demonstrating superior efficacy in treating stress-induced depression and anxiety compared to CBD alone. The study, published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, revealed that ART12.11 achieved higher plasma concentrations and enhanced activation of endocannabinoid and serotonergic systems in key brain regions.
The research, conducted with Western Ontario University, showed ART12.11 reversed stress-induced behavioral deficits more effectively than CBD alone, TMP alone, or their non-crystalline mixture. Importantly, the MHRA has agreed to allow Artelo to leverage existing CBD and TMP data for their clinical trial application, potentially accelerating the pathway to human trials planned for next year.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $3.0 million in gross proceeds. The offering consisted of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase 40,894 shares at $4.399 per warrant.
The company granted underwriters a 45-day option to purchase up to an additional 102,272 shares to cover over-allotments. R. F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's shelf registration statement.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $3.0 million public offering. The offering consists of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 102,272 shares. R.F. Lafferty & Co. is serving as the sole book-running manager. The offering, expected to close on September 5, 2025, is being made through a shelf registration statement previously filed with the SEC.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the commencement of an underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.
The securities will be offered through a "shelf" registration statement previously filed with the SEC (File No. 333-273153) and declared effective on July 14, 2023. The company focuses on developing treatments for cancer, pain, dermatologic, and neurological conditions through lipid-signaling pathway modulation.
Artelo Biosciences (Nasdaq: ARTL) has announced positive interim Phase 2 CAReS trial results for ART27.13, their treatment candidate for cancer anorexia-cachexia syndrome (CACS). The trial demonstrated significant improvements in weight, lean body mass, and activity in treated patients.
CACS affects up to 80% of cancer patients and currently has no FDA-approved treatment. Following these promising results and strong interest from multiple pharmaceutical companies, Artelo is actively pursuing partnership opportunities for ART27.13's development, stating they won't need to internally fund Phase 3 trials.
The company believes a licensing transaction represents the most value-accretive path forward for shareholders in this multi-billion-dollar potential market.
Artelo Biosciences (Nasdaq: ARTL) announced encouraging interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial for ART27.13, a treatment for cancer anorexia-cachexia syndrome (CACS). The study showed significant positive outcomes, with patients receiving the 1300 microgram dose achieving a +6.38% mean weight gain after 12 weeks, compared to -5.42% loss in placebo group.
Key highlights include a +4.23% increase in lean body mass at one month for treated patients, while placebo patients lost -3.15%. The drug demonstrated a favorable safety profile with mostly mild to moderate adverse events. The positive results are accelerating Artelo's partnering discussions with pharmaceutical companies for ART27.13, which targets CACS, a condition affecting up to 80% of cancer patients with no current FDA-approved treatment.
Artelo Biosciences (Nasdaq: ARTL) has announced positive results from its preliminary food effect evaluation of ART26.12, their novel non-opioid pain treatment candidate. The assessment was conducted as part of their successful Phase 1 single ascending dose (SAD) clinical trial.
The study demonstrated favorable safety outcomes with no serious adverse events reported. Key findings showed consistent exposure levels under fasted conditions with low inter-subject variability, indicating ART26.12 can be effectively administered with or without food. The drug showed predictable pharmacokinetics and a benign safety profile, crucial characteristics for a chronic pain treatment.
The company is now preparing to advance to a multiple ascending dose (MAD) study, scheduled to begin in Q4 2025, to further evaluate safety, tolerability, and pharmacokinetics with repeated dosing.
Artelo Biosciences (Nasdaq: ARTL) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company highlighted successful completion of Phase 1 Single Ascending Dose study for ART26.12 with positive safety results and is preparing for Multiple Ascending Dose study in Q4 2025.
Key financial metrics include Q2 net loss of $3.2 million ($5.61 per share), R&D expenses of $1.9 million, and cash position of $2.1 million. The company secured additional funding through convertible notes ($0.9M) and two PIPE transactions totaling $10.9 million.
Artelo expects multiple clinical data readouts in Q3 2025, including Phase 2 results from the CAReS study of ART27.13 for cancer anorexia-cachexia syndrome. The company also presented promising preclinical data for ART12.11 in depression treatment and plans first-in-human studies in early 2026.
Artelo Biosciences (Nasdaq: ARTL) has received a Notice of Allowance from the European Patent Office for patent application No. 21827629.3, covering the intended commercial formulation of ART27.13, their peripherally selective cannabinoid agonist. The patent protection extends through December 2041 and covers compositions of ART27.13 dispersed in polyethylene glycol.
The drug is currently in Phase 2 clinical trials (CAReS study) for cancer-related anorexia, which affects over 60% of advanced-stage cancer patients. In Phase 1, ART27.13 demonstrated positive results, with more than 60% of participants showing stabilized or reversed weight loss. Initial Phase 2 results are expected in Q3 2025.
Artelo Biosciences (Nasdaq: ARTL) has secured a $9.475 million private placement to implement a groundbreaking Solana (SOL) treasury strategy, becoming the first publicly-traded pharmaceutical company to adopt SOL as a core reserve asset. The financing includes the sale of 906,687 shares at $10.45 per share, along with two sets of three-year warrants.
The placement brings total proceeds since June 2025 to $10.9 million. Lead investor Bartosz Lipiński, former Head of Engineering at Solana Labs and Metaplex inventor, will serve as a technical partner through his company CUBE. The Board has approved expanding the SOL treasury strategy over time while maintaining adequate working capital for therapeutic development.
The private placement is expected to close around August 5, 2025, with R.F. Lafferty & Co. serving as advisor.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
